Create Account
Log In
Dark
chart
exchange
Premium
Terminal
Screener
Stocks
Crypto
Forex
Trends
Depth
Close
Check out our Dark Pool Levels

NXTC
NextCure, Inc. Common Stock
stock NASDAQ

Market Open
Jul 8, 2026 12:10:42 PM EDT
1.72USD-3.371%(-0.06)56,632
1.41Bid   1.72Ask   0.31Spread
Pre-market
Jul 7, 2026 8:59:30 AM EDT
2.07USD+16.292%(+0.29)0
After-hours
Jul 7, 2026 4:00:30 PM EDT
1.78USD-0.559%(-0.01)0
OverviewPrice & VolumeSplitsHistoricalExchange VolumeDark Pool LevelsDark Pool PrintsExchangesShort VolumeShort Interest - DailyShort InterestBorrow Fee (CTB)Failure to Deliver (FTD)ShortsTrendsNewsNews
Dec 13, 2021
08:05AM EST  NextCure and Collaborators Provide Data on Targets in Development   GlobeNewswire Inc
Nov 30, 2021
08:00AM EST  NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced that it will participate in a fireside chat at the JMP Securities Hematology and Oncology Summit on Tuesday December 7th at 11:40 am ET.   GlobeNewswire Inc
Nov 22, 2021
08:00AM EST  NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced that it will participate in the Piper Sandler Virtual 32nd Annual Healthcare Conference on November 30th.   GlobeNewswire Inc
Nov 13, 2021
02:00PM EST  NextCure and Collaborators Provide Clinical and Research Updates   GlobeNewswire Inc
Nov 12, 2021
07:47AM EST  The Daily Biotech Pulse: J&J To Spin-off Consumer Health Business, AstraZeneca Earnings, Embattled Emergent To Buy Back Shares   Benzinga
Nov 8, 2021
08:29AM EST  The Week Ahead In Biotech (Nov. 7-Nov. 13): Earnings Taper Off, Multiple Conference Presentations, IPOs And More   Benzinga
Nov 5, 2021
09:44AM EDT  Needham Maintains Buy on NextCure, Lowers Price Target to $14   Benzinga
09:32AM EDT  NextCure Q3 EPS $(0.65) Down From $(0.59) YoY   Benzinga
Nov 1, 2021
08:00AM EDT  NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced that the company will host a Virtual Oncology Pipeline Update Event at 4:30 p.m. ET on Monday, November 15, 2021.   GlobeNewswire Inc
Oct 19, 2021
08:05AM EDT  NextCure Announces Three New Members of its Scientific Advisory Board   GlobeNewswire Inc
Oct 7, 2021
04:06PM EDT  NextCure Announces Publication Of Preclinical Data for NC410   Benzinga
Oct 4, 2021
08:19AM EDT  NextCure Appoints Ellen Feigal And Anne Borgman To Board   RTTNews
08:05AM EDT  NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced the appointments of Ellen G. Feigal, M.D., and Anne Borgman, M.D., to its Board of Directors.   GlobeNewswire Inc
Oct 1, 2021
08:45AM EDT  NextCure to Give Three Presentations at Society for Immunotherapy   GlobeNewswire Inc
07:56AM EDT  The Daily Biotech Pulse: Merck Rallies On Antiviral Pill Data, Gilead Files For Yescarta Label Expansion, Exscientia IPO   Benzinga
Sep 23, 2021
07:57AM EDT  The Daily Biotech Pulse: Restricted Authorization For Pfizer's COVID-19 Booster Dose, AbCellera Strikes Antibody Licensing Deal, Solid Biosciences Issues DMD Data   Benzinga
Sep 7, 2021
07:00AM EDT  NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced that it will present at the H.C. Wainwright 23rd Annual Global Investment Conference on September 13th.   GlobeNewswire Inc
Sep 2, 2021
07:00AM EDT  NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced that it will participate in a fireside chat at the 19th Annual Morgan Stanley Global Healthcare Conference on September 9th at 12:30 pm Eastern time.   GlobeNewswire Inc
Aug 5, 2021
04:59PM EDT  NextCure Q2 EPS $(0.65) Down From $(0.53) YoY   Benzinga
Jul 28, 2021
07:33AM EDT  The Daily Biotech Pulse: Pfizer, Bristol-Myers Squibb Earnings, Amgen Goes Shopping, GlaxoSmithKline-Vir's COVID-19 Antibody Treatment Supply Deal   Benzinga
Jul 27, 2021
11:13AM EDT  The Daily Biotech Pulse: ObsEva Surges On Out-Licensing Deal, EyeGate Appoints New CEO, 2 Positive Catalysts For Merck, Candel Therapeutics Debuts   Benzinga
Jul 20, 2021
08:20AM EDT  The Daily Biotech Pulse: Ardelyx Sinks On Regulatory Setback, AnPac Issues Positive Preannouncement, European Nod For Myovant, HCW Biologics Debuts On Wall Street   Benzinga
Jul 16, 2021
07:37AM EDT  The Daily Biotech Pulse: Moderna To Join S&P 500 Index, Thumbs Down For FibroGen's Anemia Drug, Corvus Shelves COVID Study   Benzinga
Jul 15, 2021
08:08AM EDT  The Daily Biotech Pulse: Galapagos Sinks On Data, J&J Recalls Sunscreen Products, FibroGen Awaits AdCom Verdict, 3 IPOs   Benzinga
Jul 14, 2021
07:48AM EDT  The Daily Biotech Pulse: ScPharma's Positive Data, Lilly Goes Shopping, LeMaitre Pre-Announces Q2 Revenues   Benzinga
Jul 7, 2021
08:06AM EDT  NextCure Launches Early-Stage Study For NC762 In Solid Tumor Settings   Benzinga
07:41AM EDT  The Daily Biotech Pulse: Opiant Spikes On Data, OncoSec Rallies On Merck Collaboration, XBiotech Special Dividend   Benzinga
Jul 6, 2021
04:06PM EDT  NextCure Initiates Phase 1/2 Clinical Trial of NC762 for Solid Tumors   Benzinga
04:05PM EDT  NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced the initiation of a Phase 1/2 clinical trial for NC762, a humanized B7-H4 monoclonal antibody.   GlobeNewswire Inc
Jun 22, 2021
08:12AM EDT  The Daily Biotech Pulse: Sanofi, Translate Bio Start Early Stage Seasonal Flu Vaccine Study, Dr. Reddy's Launches Generic Vascepa, Halozyme Strikes Licensing Deal   Benzinga
06:34AM EDT  NextCure's Immunomedicine NC410 Shows Promising Anti-Cancer Activity In Preclinical Studies   Benzinga
Jun 21, 2021
04:05PM EDT  NextCure and Collaborators Publish Preclinical Data on Novel Immunomedicine NC410   Benzinga
04:05PM EDT  NextCure and Collaborators Publish Preclinical Data on Novel   GlobeNewswire Inc
Jun 10, 2021
04:10PM EDT  NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced that it will participate in a fireside chat at the JMP Securities Life Sciences Conference on June 17th at 1:30 pm Eastern time.   GlobeNewswire Inc
May 19, 2021
06:05PM EDT  NextCure to Present Trials in Progress Poster for NC410 at the   GlobeNewswire Inc
May 12, 2021
08:57AM EDT  The Daily Biotech Pulse: Minerva, InflaRx Report Positive Data Readouts, Lucira COVID-19 Test Kit Available On Amazon, Decision Day For Heron   Benzinga
May 6, 2021
05:54PM EDT  NextCure Q1 EPS $(0.60) Down From $0.33 YoY   Benzinga
07:49AM EDT  The Daily Biotech Pulse: Merck's Keytruda Snags Another FDA Approval, Moderna Slips On Revenue Miss, Chemocentryx Adcom   Benzinga
May 5, 2021
04:22PM EDT  NextCure To Present At The BofA Securities 2021 Virtual Health Care Conference May 12   Benzinga
04:10PM EDT  NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced that it will participate in a fireside chat at the BofA Securities 2021 Virtual Health Care Conference on May 12th at 2:00 pm Eastern time.   GlobeNewswire Inc
Apr 12, 2021
10:15AM EDT  NextCure Saturday Morning Announced Preclinical Data For NC762 At American Association For Cancer Research Conference   Benzinga
Apr 10, 2021
08:30AM EDT  NextCure Presents Preclinical Data for NC762 at American   GlobeNewswire Inc
Apr 7, 2021
04:05PM EDT  NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced that it will present at the 20th Annual Needham Virtual Healthcare Conference on April 13th at 12:45 pm Eastern time.   GlobeNewswire Inc
Mar 5, 2021
10:48AM EST  NextCure shares were trading higher after the company issued FY20 EPS results up from last year. Truist Securities upgraded the stock from Hold to Buy and raised its price target from $13 to $19 per share.   Benzinga
10:29AM EST  Benzinga's Top Ratings Upgrades, Downgrades For March 5, 2021   Benzinga
07:51AM EST  Truist Securities Upgrades NextCure to Buy, Raises Price Target to $19   Benzinga
Mar 4, 2021
04:19PM EST  NextCure FY20 EPS $(1.33), Up From $(2.15) YoY   Benzinga
04:05PM EST  NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today reported fourth quarter and full year 2020 financial results and provided a business update.   GlobeNewswire Inc
Jan 28, 2021
11:01AM EST  Class Action Lawsuit Against NextCure, Inc. and Encourages Investors with Losses to Contact the Firm   PR Newswire
Jan 15, 2021
10:07AM EST  Benzinga's Top Ratings Upgrades, Downgrades For January 15, 2021   Benzinga
08:08AM EST  B of A Securities Downgrades NextCure to Underperform, Lowers Price Target to $10   Benzinga
Jan 14, 2021
04:05PM EST  NextCure Appoints Dr. Han Myint As Cheif Medical Officer   Benzinga
04:05PM EST  Dr. Han Myint Appointed as NextCures Chief   GlobeNewswire Inc
Dec 17, 2020
07:08AM EST  NextCure Provides Updates On NC318 Clinical Program; Says At This Time, No Longer Plans To Initiate Study Of NC318 In Combination With Chemotherapy   Benzinga
07:05AM EST  NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today provided an update on the clinical trial program for NC318, its first-in-class immunomedicine against Siglec15 (S15), a novel immunomodulatory target.   GlobeNewswire Inc
Nov 26, 2020
03:24AM EST  Pomerantz LLP is investigating claims on behalf of investors of NextCure (NextCure or the Company) (NASDAQ:NXTC). Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. 7980.   GlobeNewswire Inc
Nov 23, 2020
04:05PM EST  NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced that it will participate in a fireside chat at the Piper Sandler Virtual 32nd Annual Healthcare Conference on December 1st.   GlobeNewswire Inc
Nov 22, 2020
03:24AM EST  Pomerantz LLP is investigating claims on behalf of investors of NextCure (NextCure or the Company) (NASDAQ:NXTC). Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. 7980.   GlobeNewswire Inc
Nov 20, 2020
09:28AM EST  Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against NextCure Inc.   PR Newswire
Nov 19, 2020
08:00AM EST  Investors with losses are encouraged to contact the firm before November 20, 2020; click here to submit trade information   GlobeNewswire Inc
Nov 18, 2020
11:06AM EST  NXTC INVESTOR FILING DEADLINE: Bernstein Liebhard Reminds   GlobeNewswire Inc
Nov 16, 2020
11:15AM EST  The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion.   GlobeNewswire Inc
Nov 14, 2020
02:00PM EST  Important November 20 Deadline in Securities Class Action; Encourages Investors with Losses in Excess of $100K to Contact Firm - NXTC   PR Newswire
Nov 13, 2020
12:00PM EST  DEADLINE ALERT for GOCO, NXTC, WRTC, GLNG: Law Offices of Howard G   GlobeNewswire Inc
Nov 11, 2020
04:47PM EST  Pomerantz LLP is investigating claims on behalf of investors of NextCure (NextCure or the Company) (NASDAQ:NXTC). Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. 7980.   GlobeNewswire Inc
02:51PM EST  Zhang Investor Law announces a class action lawsuit on behalf of shareholders who bought shares of NextCure, Inc. (NASDAQ: NXTC) (1) between November 5, 2019 and July 14, 2020, inclusive (the Class Period); and/or (2) pursuant or traceable to NextCures November 2019 secondary public offering.   GlobeNewswire Inc
12:30PM EST  Shareholders with $100,000 losses or more are encouraged to contact the firm   GlobeNewswire Inc
Nov 10, 2020
05:17PM EST  Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against NextCure Inc.   PR Newswire
04:00PM EST  ROSEN, A TOP RANKED LAW FIRM, Reminds NextCure, Inc. Investors of   GlobeNewswire Inc
Nov 9, 2020
11:00AM EST  The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion.   GlobeNewswire Inc
Nov 6, 2020
11:07AM EST  SHAREHOLDER DEADLINE: Pawar Law Group Announces a Securities Class   GlobeNewswire Inc
Nov 5, 2020
04:54PM EST  NextCure Q3 EPS $(0.59) Down From $(0.37) YoY   Benzinga
Nov 3, 2020
11:00AM EST  The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion.   GlobeNewswire Inc
Oct 30, 2020
08:45PM EDT  ROSEN, GLOBAL INVESTOR COUNSEL, Reminds NextCure, Inc. Investors   GlobeNewswire Inc
11:00AM EDT  Shareholders with $100,000 losses or more are encouraged to contact the firm   GlobeNewswire Inc
Oct 28, 2020
08:38PM EDT  Important November 20 Deadline in Securities Class Action; Encourages Investors with Losses in Excess of $100K to Contact Firm - NXTC   PR Newswire
12:30PM EDT  Law Offices of Howard G. Smith reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion.   GlobeNewswire Inc
Oct 27, 2020
04:16PM EDT  Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against NextCure Inc.   PR Newswire
12:00PM EDT  The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion.   GlobeNewswire Inc
Oct 23, 2020
10:23AM EDT  NXTC INVESTOR FILING DEADLINE: Bernstein Liebhard Reminds   GlobeNewswire Inc
Oct 22, 2020
11:30AM EDT  Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class   PR Newswire
Oct 21, 2020
01:00PM EDT  NXTC, FLDM & WRTC Class Action Reminders: Bronstein, Gewirtz &   GlobeNewswire Inc
12:00PM EDT  The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion.   GlobeNewswire Inc
Oct 20, 2020
11:00AM EDT  Law Offices of Howard G. Smith reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion.   GlobeNewswire Inc
Oct 15, 2020
05:15PM EDT  ROSEN, A LEADING AND RANKED FIRM, Reminds NextCure, Inc. Investors   GlobeNewswire Inc
02:19PM EDT  The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion.   GlobeNewswire Inc
11:30AM EDT  Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline   GlobeNewswire Inc
Oct 14, 2020
01:16PM EDT  NXTC INVESTOR FILING DEADLINE: Bernstein Liebhard Reminds   GlobeNewswire Inc
Oct 13, 2020
01:46PM EDT  Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against NextCure Inc.   PR Newswire
Oct 12, 2020
11:21PM EDT  Pomerantz LLP is investigating claims on behalf of investors of NextCure (NextCure or the Company) (NASDAQ:NXTC). Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. 7980.   GlobeNewswire Inc
12:00PM EDT  Law Offices of Howard G. Smith reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion.   GlobeNewswire Inc
Oct 9, 2020
04:45PM EDT  Important Deadline in Securities Class Action; Encourages Investors with Losses in Excess of $100K to Contact the Firm - NXTC   PR Newswire
12:05AM EDT  Pomerantz LLP is investigating claims on behalf of investors of NextCure (NextCure or the Company) (NASDAQ:NXTC). Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. 7980.   GlobeNewswire Inc
Oct 8, 2020
07:36PM EDT  Investors with a $100,000 or more in losses are encouraged to contact the firm.   GlobeNewswire Inc
11:31AM EDT  DEADLINE REMINDER: Law Offices of Howard G. Smith Reminds Investors of Looming   PR Newswire
11:30AM EDT  The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion.   GlobeNewswire Inc
08:00AM EDT  LAWSUITS FOR SECURITIES VIOLATIONS FILED AGAINST NXTC AND WRTC:   GlobeNewswire Inc
Oct 7, 2020
10:09AM EDT  NXTC INVESTOR FILING DEADLINE: Bernstein Liebhard Reminds   GlobeNewswire Inc
Oct 6, 2020
07:15PM EDT  ROSEN, NATIONAL TRIAL LAWYERS, Reminds NextCure, Inc. Investors of   GlobeNewswire Inc
01:23PM EDT  The Law Offices of Frank R. Cruz Announces the Filing of a Securities Class   PR Newswire
Oct 3, 2020
01:30PM EDT  LEAD PLAINTIFF DEADLINE: Johnson Fistel, LLP Encourages Investors to Contact   PR Newswire
Oct 2, 2020
11:45AM EDT  The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion.   GlobeNewswire Inc
11:00AM EDT  NXTC Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Notifies NextCure, Inc. Investors of Class Action and Encourages Shareholders to Contact the Firm   Business Wire
Oct 1, 2020
08:45AM EDT  LAWSUITS FOR SECURITIES VIOLATIONS FILED AGAINST NXTC AND WRTC:   GlobeNewswire Inc
Sep 30, 2020
06:58PM EDT  Pomerantz LLP is investigating claims on behalf of investors of NextCure (NextCure or the Company) (NASDAQ:NXTC). Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. 7980.   GlobeNewswire Inc
11:11AM EDT  NXTC INVESTOR FILING DEADLINE: Bernstein Liebhard Reminds   GlobeNewswire Inc
Sep 29, 2020
02:50PM EDT  Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against NextCure Inc.   PR Newswire
Sep 28, 2020
08:00PM EDT  Against NextCure, Inc.; Encourages Investors with Losses in Excess of $100K to Contact the Firm - NXTC   PR Newswire
10:29AM EDT  NXTC SHAREHOLDER ALERT: Bernstein Liebhard Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against NextCure Inc.   Business Wire
Sep 27, 2020
02:44PM EDT  Pomerantz LLP is investigating claims on behalf of investors of NextCure (NextCure or the Company) (NASDAQ:NXTC). Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. 7980.   GlobeNewswire Inc
Sep 25, 2020
07:00PM EDT  ROSEN, GLOBAL INVESTOR COUNSEL, Announces Filing of Securities   GlobeNewswire Inc
06:30PM EDT  SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of   PR Newswire
10:02AM EDT  NXTC SHAREHOLDER ALERT: Bernstein Liebhard Announces that a Securities Class Action Lawsuit has Been Filed Against NextCure Inc.   Business Wire
10:00AM EDT  NXTC Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC   GlobeNewswire Inc
Sep 24, 2020
10:21AM EDT  NXTC LOSSES ALERT: Bernstein Liebhard is Investigating NextCure Inc. For Violations of the Securities Laws   Business Wire
Sep 23, 2020
04:15PM EDT  NEXTCURE, INC. CLASS ACTION ALERT: Wolf Haldenstein Adler Freeman   GlobeNewswire Inc
10:00AM EDT  Inc. Investors of Class Action and Encourages Shareholders to Contact the Firm   PR Newswire
09:03AM EDT  NXTC INVESTOR ALERT: Bernstein Liebhard is Investigating NextCure Inc. For Violations of the Securities Laws   Business Wire
Sep 22, 2020
04:42PM EDT  Gainey McKenna & Egleston Announces A Class Action Lawsuit Has   GlobeNewswire Inc
12:37PM EDT  Kehoe Law Firm, P.C. is investigating potential securities claims on behalf of investors of NextCure, Inc. (NextCure or the Company) (NASDAQ: NXTC) to determine whether the Company engaged in securities fraud or other unlawful business practices.   GlobeNewswire Inc
11:17AM EDT  SHAREHOLDER ALERT: NextCure, Inc. Sued for Violations of the   GlobeNewswire Inc
Sep 14, 2020
04:05PM EDT  NextCure Announces Appointment of John G. Houston, Ph.D., to its   GlobeNewswire Inc
Sep 8, 2020
08:05AM EDT  NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced that it will present at the Morgan Stanley Virtual 18th Annual Global Healthcare Conference on September 15th at 4:15 pm Eastern time.   GlobeNewswire Inc
Aug 6, 2020
05:55PM EDT  NextCure Inc Files For Potential Mixed Shelf Offering; Size Not Disclosed   Benzinga
04:41PM EDT  NextCure Q2 EPS $(0.53) Up From $(0.61) YoY   Benzinga
Aug 5, 2020
08:05AM EDT  NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced that it will present at the BTIG Virtual Biotechnology Conference on August 11th at 9:30 am Eastern time.   GlobeNewswire Inc
Jul 16, 2020
07:06AM EDT  Benchmark Upgrades NextCure to Buy, Announces $17 Price Target   Benzinga
Jul 15, 2020
11:45AM EDT  Scott+Scott Attorneys at Law LLP Announces Investigation into NextCure, Inc.   PR Newswire
04:49AM EDT  55 Biggest Movers From Yesterday   Benzinga
Jul 14, 2020
07:51AM EDT  BTIG Maintains Buy on NextCure, Lowers Price Target to $27   Benzinga
05:11AM EDT  80 Biggest Movers From Yesterday   Benzinga
Jul 13, 2020
04:45PM EDT  04:45 Monday, July 13, 2020   RTTNews
02:31PM EDT  Mid-Afternoon Market Update: Dow Jumps 400 Points; Equillium Shares Spike Higher   Benzinga
12:01PM EDT  Mid-Day Market Update: Benefytt Technologies Surges Following Acquisition News; NextCure Shares Slide   Benzinga
10:23AM EDT  Shares of NextCure, Inc. (NXTC) are losing more than 41 percent or $7.36 in Monday's morning trade at $10.52, after earlier touching a new 52-week low of $10.45.   RTTNews
10:13AM EDT  Mid-Morning Market Update: Markets Open Higher; PepsiCo Beats Q2 Estimates   Benzinga
09:39AM EDT  SunTrust Robinson Humphrey Downgrades NextCure to Hold, Lowers Price Target to $13   Benzinga
06:18AM EDT  NextCure's Chief Medical Officer Resigns to Pursue Other Opportunities   Benzinga
06:13AM EDT  NextCure Provides Interim Update For Phase 2 Portion Of NC318 Monotherapy Phase 1/2 Trial   RTTNews
06:08AM EDT  NextCure Says Does Not Plan to Advance the Non-small Cell Lung Cancer (Nsclc) and Ovarian Cancer Cohorts Into the Stage 2 Portion of the Simon 2-stage Trial   Benzinga
06:05AM EDT  NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today provided an interim update for the Phase 2 portion of its NC318 monotherapy phase 1/2 trial.   GlobeNewswire Inc


Share
About
Pricing
Policies
Markets
API
Info
tz UTC-4
Connect with us
ChartExchange Email
ChartExchange on Discord
ChartExchange on X
ChartExchange on Reddit
ChartExchange on GitHub
ChartExchange on YouTube
© 2020 - 2026 ChartExchange LLC